XtalPi(QuantumPharm Inc.,stock code: 2228.HK) is an innovative research platform company powered by artificial intelligence (AI) and robotics. Established in 2015 by three postdoctoral physicists at MIT, XtalPi is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and advanced materials industries globally.
-
783
Employees
-
500+
Scientists and technologists
-
39
Ongoing drug discovery programs
-
160+
Granted patents
XtalPi Global Facilities
-
Boston
USA
Cambridge Innovation Center (CIC), Kendall Square
XtalPi Boston Site plays a key role in leading the business development efforts for clients in the United States, Europe, and some parts of Asia. The site also collaborates with pharmaceutical companies and scientific research institutions to drive innovation and growth in the industry.
-
Shenzhen
China
Shenzhen Futian District International Biomedical Industrial Park
Center for corporate operations and main R&D center
Includes a full-scale synthetic chemistry lab, a pharmaceutical solid state R&D Lab and a drug discovery biology lab that together enable drug design and deliver solid-state research under our "A.I. computing + experiment" model.
-
Shanghai
China
Shanghai Free Trade No. 1 Life Science and Technology Industrial Park
XtalPi Shanghai Site offers an all-in-one drug discovery platform for small molecules and biologics, as well as cutting-edged modeling, automated synthetic chemistry, and biology services.
Visit XtalPi Shanghai Automated Web Lab Online >>
Shanghai Zhangjiang Science City
Center for greater China business operations and development
-
Beijing
China
Beijing Zhong Guan Cun Science Park (Z-Park)
Committed to driving drug discovery innovation with big data and deep learning algorithms, and providing technology and services for drug discovery.
History
2015
Founded XtalPi to provide crystal structure prediction and drug research development services
Began to develop a research platform to study the solid-state form of drugs
2016
AI R&D center was officially registered and established
Established a CSP platform for crystal form prediction
Our CSP platform was proven accurate in a blind test held by Pfizer
Completed Series Pre-A Financing, Series A-1 Financing and Series A-2 Financing which had first launched since 2015
2017
Launched an AI-powered integrated technology platform "Atompai" and an AI-powered drug discovery platform "Renova"
Began cooperation with Pfizer to provide polymorph screening and selection service
Completed Series B Financing
2018
Developed the XFF high-precision force field
Developed XFEP for free energy perturbation calculations
Established wet lab facilities for solid-state R&D, synthesis and experimental research
Developed a drug discovery platform for small molecules
Completed Series B+ Financing
2019
Began to develop a drug discovery platform for antibody, peptide and protein therapeutics
Completed Series B++ Financing
2020
Started R&D of automation laboratory and completed development and concept certification on the prototype machine of the automation station
Completed Series C Financing
2021
Completed the development of the experimental and computing R&D center in Futian, Shenzhen
Completed the development of the pharmaceutical innovation R&D center in Pudong, Shanghai
Developed an antibody discovery platform "XupremAb"
Completed Series D Financing
2022
Built-up a scalable and standardized intelligent robotic wet labs
2023
Developed a proprietary ProteinGPT
Entered into an AI small molecule drug discovery collaboration worth up to US$250 million with Lilly
Established an innovative demo lab in Boston, Massachusetts
Unveiled the brands "XtalPi Drug Discovery" and "XtalPi Intelligent Automation"
2015
2016
2017
2018
2019
2020
2021
2022
2023
Founding Team
-
Wen Shuhao
Co-founder/Executive Director and chairman of our Board
Read More
-
Ma Jian
Co-founder/Executive Director and Chief Executive Officer
Read More
-
Lai Lipeng
Co-founder/Executive Director and Chief Innovation Officer
Read More
Honors and Awards
-
National high-tech enterprise
-
ISO27001 Information Security Management System Certification
-
2021 Forbes China Enterprise Technology 50
-
2021 Venture50 Top 50 / Venture50 Top 50 Digital Technology
-
2021 “Star of the Future”, one of 21 high-growth innovation companies in 2021
-
2020 MIT Technology Review – 50 Smartest Companies in China (TR50 China)
-
2020 Deloitte - China Technology Fast 50
-
2020 Ernst & Young, Fudan University – China’s Most Promising Companies
-
2020 CB Insights Research - Digital Health 150
-
2020 36Kr - AI Top 50, Nomination for ‘King of the New Infrastructure’
Sustainable Development
Our mission is a world of smarter science, better lives.
We aim to accelerate the design and discovery of novel drugs and materials leveraging quantum physics, AI and robotic automation.
Case Study
Helping Pfizer accelerate development of novel COVID-19 oral antiviral drug PAXLOVID
PAXLOVID is the world's first FDA-approved oral COVID-19 drug developed by Pfizer and sold around the world. To expedite the development of PAXLOVID (PF-07321332), Pfizer and XtalPi worked closely together, combining XtalPi's digital prediction algorithm and experimental validation. It took only six weeks for the teams to complete mutual validation and precise matching of drug crystal structure prediction against the experimental results, making possible the subsequent development and production.
XtalPi's computational prediction provided powerful evidence of the crystal structure designed by Pfizer being the most stable crystal structure under room temperature, thus making it suitable for scale-up and production. In this way CMC scientists were able to rapidly make research decisions and begin the process without delay.
As an oral drug, PAXLOVID was developed in solid state to facilitate storage and transportation. Patients can self-administer the drug at home, leading to greater compliance, thus helping to alleviate the tremendous strain on the medical system at the height of the COVID-19 pandemic.